{"id":15987,"date":"2025-01-03T16:38:56","date_gmt":"2025-01-03T09:38:56","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=15987"},"modified":"2025-01-03T16:38:56","modified_gmt":"2025-01-03T09:38:56","slug":"hanx-biopharmaceuticals-ltd-announces-first-patient-dosing-in-first-in-human-phase-1-clinical-trial-of-hx044","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=15987","title":{"rendered":"Hanx Biopharmaceuticals, Ltd. Announces First Patient Dosing in First-in-Human Phase 1 Clinical Trial of HX044"},"content":{"rendered":"

WUHAN, China<\/span>, Jan. 3, 2025 \/PRNewswire\/ — Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical need diseases, today announced the first patient dosing in Australia<\/span> on Dec 30, 2024<\/span> for Phase 1 clinical trial of HX044 in patients with advanced solid tumors (HX044-I-01, A Phase I\/IIa, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HX044 in Patients with Advanced Solid Tumor Malignancies, NCT06649708).<\/span><\/p>\n

HX044 is an innovative bispecific antibody independently developed by Hanx<\/span>\u00a0Biopharmaceuticals. It is a first-in-class and considered to be a next generation immune-checkpoint inhibitor designed to treat a wide range of malignant tumors, including PD-1-resistant solid tumors such as non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, and gastrointestinal cancers. HX044 represents a new generation CTLA-4 immunotherapy by expanding the therapeutic window, optimizing safety, and enhancing antitumor immune responses, showcasing a breakthrough in CTLA-4 immunotherapy.<\/p>\n

“We are thrilled to see the first patient entered into clinical study, which marks a significant development milestone for this therapeutic candidate in our pipeline. This achievement demonstrated our strong R&D and clinical development capacity, and it reflects our commitment to addressing unmet medical needs for the patients. We will be working diligently to move this project forward”, said Dr.\u00a0Faming Zhang, Chairman of Hanx Biopharmaceuticals. “HX044 is a next generation CTLA-4 bispecific antibody fully developed in-house by the company, starting from molecule design. It enhances Treg<\/sub>-depletion function within tumor microenvironment through its effective cis-binding mechanism. It shows strong efficacy even against PD-1-resistant “cold” tumors in preclinical models, demonstrating superior therapeutic potential”, commended by Dr. Henry Li<\/span>, CEO\/CSO of Hanx Biopharmaceuticals.<\/p>\n

About HANX BIOPHARMACEUTICALS<\/b><\/p>\n

Hanx Biopharmaceutical Co., Ltd. is an innovative biotechnology company dedicated to structural biology, translational medicine, and clinical development. The company strives to develop next-generation immunotherapies to provide global patients with affordable, safe, and effective medical solutions, addressing the challenges of major diseases. Guided by a mission and vision driven by innovation, Hanx<\/span> Biopharmaceuticals focuses on discovering, developing, and commercializing First-in-Class and Best-in-Class therapies for cancer and autoimmune diseases. The company is committed to meeting unmet medical needs worldwide, advancing disease prevention, control, and ultimately elimination, and contributing to global health initiatives.<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

WUHAN, China<\/span>, Jan. 3, 2025 \/PRNewswire\/ — Hanx Biopharmaceuticals, CO. Ltd, an innovative biotechnology company developing next-generation immunotherapies to address the challenges of unmet medical need diseases, today announced the first patient dosing in Australia<\/span> on Dec 30, 2024<\/span> for Phase 1 clinical trial of HX044 in patients with advanced solid tumors (HX044-I-01, A Phase I\/IIa, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HX044 in Patients with Advanced Solid Tumor Malignancies, NCT06649708).<\/span><\/p>\n

HX044 is an innovative bispecific antibody independently developed by Hanx<\/span>\u00a0Biopharmaceuticals. It is a first-in-class and considered to be a next generation immune-checkpoint inhibitor designed to treat a wide range of malignant tumors, including PD-1-resistant solid tumors such as non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, and gastrointestinal cancers. HX044 represents a new generation CTLA-4 immunotherapy by expanding the therapeutic window, optimizing safety, and enhancing antitumor immune responses, showcasing a breakthrough in CTLA-4 immunotherapy.<\/p>\n

“We are thrilled to see the first patient entered into clinical study, which marks a significant development milestone for this therapeutic candidate in our pipeline. This achievement demonstrated our strong R&D and clinical development capacity, and it reflects our commitment to addressing unmet medical needs for the patients. We will be working diligently to move this project forward”, said Dr.\u00a0Faming Zhang, Chairman of Hanx Biopharmaceuticals. “HX044 is a next generation CTLA-4 bispecific antibody fully developed in-house by the company, starting from molecule design. It enhances Treg<\/sub>-depletion function within tumor microenvironment through its effective cis-binding mechanism. It shows strong efficacy even against PD-1-resistant “cold” tumors in preclinical models, demonstrating superior therapeutic potential”, commended by Dr. Henry Li<\/span>, CEO\/CSO of Hanx Biopharmaceuticals.<\/p>\n

About HANX BIOPHARMACEUTICALS<\/b><\/p>\n

Hanx Biopharmaceutical Co., Ltd. is an innovative biotechnology company dedicated to structural biology, translational medicine, and clinical development. The company strives to develop next-generation immunotherapies to provide global patients with affordable, safe, and effective medical solutions, addressing the challenges of major diseases. Guided by a mission and vision driven by innovation, Hanx<\/span> Biopharmaceuticals focuses on discovering, developing, and commercializing First-in-Class and Best-in-Class therapies for cancer and autoimmune diseases. The company is committed to meeting unmet medical needs worldwide, advancing disease prevention, control, and ultimately elimination, and contributing to global health initiatives.<\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-15987","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/15987","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15987"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/15987\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15987"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15987"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15987"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}